Monitor for future equity grant volumes under the expanded plan. The incremental 1.8% potential dilution is modest and typical for growth-stage healthcare services companies. No immediate trading catalyst.
Price Chart
Executive Summary
Astrana Health filed an 8-K reporting the results of its 2026 Annual Meeting of Stockholders, where shareholders approved an amendment and restatement of the 2024 Equity Incentive Plan, increasing the share reserve by 1,000,000 shares to a total of 5,100,000 shares and extending the plan's term to March 2036. Nine directors were re-elected, and Ernst & Young was ratified as the independent auditor. This is a routine governance filing with no material financial impact.
Key Facts
- Shareholders approved an amendment to the 2024 Equity Incentive Plan, increasing the share reserve by 1,000,000 shares to 5,100,000 total shares.
- The plan term was extended to March 24, 2036.
- Nine directors were elected at the Annual Meeting held June 10, 2026.
- Ernst & Young LLP was ratified as the independent registered public accounting firm for fiscal 2026.
- Approximately 78.6% of outstanding shares were represented at the meeting, constituting a quorum.
- CEO Brandon K. Sim signed the filing.
Financial Impact
Share count increase of 1,000,000 shares (approximately 1.8% of the 55,713,532 outstanding shares) authorized for equity grants; no immediate P&L impact.
Risk Factors
- Future equity grants under the expanded plan could result in up to ~1.8% dilution to existing shareholders over time.
- No other material risks identified from this routine governance filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-072343 |
| Document: tm2614755d1_8k.htm | 0001104659-26-072343 |
| Document: 0001104659-26-072343-index-headers.html | 0001104659-26-072343 |
| Document: 0001104659-26-072343-index.html | 0001104659-26-072343 |
| Document: 0001104659-26-072343.txt | 0001104659-26-072343 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 23, 2026 4w ago | 8-K | $34.34 $37.35 | ▲ +8.77% | ▲ +8.08% | $36.94 (+7.57%) |
Sep 23, 2026 4w ago | 8-K | $34.34 $37.35 | ▼ −8.77% | ▼ −8.08% | $36.94 (−7.57%) |
Sep 15, 2026 6w ago | 8-K | $38.35 $37.87 | ▼ −1.25% | ▼ −4.23% | $36.94 (−3.68%) |
Jul 14, 2026 15w ago | Press Release | $47.04 $35.79 | ▼ −23.92% | ▼ −26.26% | $36.94 (−21.47%) |
Jul 13, 2026 15w ago | 8-K | $47.64 $37.47 | ▼ −21.35% | ▼ −24.53% | $36.94 (−22.46%) |
Jun 10, 2026 19w ago | 8-K | $39.85 $46.81 | ▲ +17.47% | ▲ +15.57% | $36.94 (−7.30%) |
Apr 17, 2026 27w ago | DEFA14A | $31.50 $39.16 | ▲ +24.32% | ▲ +18.95% | $36.94 (+17.27%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers